Monoclonal Patents (Class 530/388.1)
  • Patent number: 10611839
    Abstract: An isolated antibody comprising an antigen recognition domain which specifically binds CD84 and (i) down regulates the anti-apoptotic activity of stromal cells on chronic lymphocytic leukemia (CLL) cells; and/or (ii) induces mobilization of CLL cells from the bone marrow. Also provided are antibodies comprising antigen recognition domains comprising complementarity determining regions as indicated and uses thereof.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: April 7, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Idit Shachar, Inbal Binsky, Ayelet Marom
  • Patent number: 10519223
    Abstract: The invention provides an antibody or antigen binding fragments thereof that binds to 3pE A? and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: December 31, 2019
    Assignee: Jannsen Pharmaceutica NV
    Inventors: Marc Mercken, Bianca Van Broeck, Marc Vandermeeren, Bart Hermans, Astrid Bottelbergs
  • Patent number: 10464997
    Abstract: The present invention provides a method for making uncapped cysteine protein preparations, including uncapped engineered cysteine antibody preparations. The methods include, inter alia, contacting a reducing agent with engineered cysteine antibody molecules, each of the antibody molecules having at least one capped engineered cysteine residue and at least one interchain disulfide bond and reacting the reducing agent with the antibody molecules under conditions sufficient to uncap engineered cysteine residues and form cap byproducts. The method also includes removing the cap byproduct during the reduction reaction. Substantially all of the interchain disulfide bonds present in the antibody molecules prior to reduction are retained following reduction. Antibody conjugates and methods for preparing antibody conjugates using uncapped antibody preparations are also described.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: November 5, 2019
    Assignee: Seattle Genetics, Inc.
    Inventor: Damon L. Meyer
  • Patent number: 10465009
    Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates and uses thereof.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: November 5, 2019
    Assignee: Amgen Inc.
    Inventors: Richard J. Armitage, Michelle Blake, William C. Fanslow, III, Jason Charles O'Neill, Gunasekaran Kannan, Jiangchun Xu, Mark Edward Tometsko, Zhulun Wang, Athena Sudom
  • Patent number: 10316059
    Abstract: The present invention is directed to methods comprising the use of hydroxyapatite chromatography to separate a bispecific antibody from a solution that also comprises one or more byproducts specific to bispecific antibody production. Byproducts specific to the production of bispecific antibodies (bispecific antibody specific byproducts, “BASB”) include fragments of the bispecific antibody and heavier molecular weight variants of the antibody, wherein the fragment and/or variant comprises an Fc domain but does not exhibit affinity for the two different epitopes and/or antigens as exhibited by the desired bispecific antibody. Thus, the methods of the present invention comprise the separation of a bispecific antibody from one or more of its BASB. The hydroxyapatite chromatography methods of the invention may be used alone or may be further combined with standard purification processes and unit operations as is known in the art to achieve any level of purity of bispecific antibody necessary, e.g.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: June 11, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sabine Bertl, Harald Duerr, Andreas Schaubmar
  • Patent number: 10253340
    Abstract: Disclosed is a method for the isomerization of glucose by reduction to sorbitol and subsequent oxidation to fructose, in which the redox cofactors NAD+/NADH and NADP+/NADPH are regenerated in a one-pot-reaction, wherein one of the two redox cofactors is obtained in the reduced form thereof and the other redox cofactor in the oxidized form thereof as a result of at least two additional enzymatically catalyzed redox reactions (product forming reactions) taking place in the same reaction batch, wherein a) in the regeneration reaction, which transfers the reduced cofactor back to its originally oxidized form, oxygen or a compound of the general formula R1C(O)COOH is reduced, and b) in the regeneration reaction, which transfers the oxidized cofactor back to its originally reduced form, a compound of the general formula R2CH(OH)R3 is oxidized, wherein R1, R2 and R3 have different meanings in the compounds, characterized in that a mixture of glucose and fructose is used as a starting material.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: April 9, 2019
    Assignee: ANNIKKI GMBH
    Inventor: Ortwin Ertl
  • Patent number: 10239944
    Abstract: The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: March 26, 2019
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Carlos J. Bosques, James S. Huston, Jonathan C. Lansing, Leona E. Ling, James Meador, III, Daniel Ortiz, Laura Rutitzky
  • Patent number: 10047144
    Abstract: The invention provides methods of purifying antibodies using various antibody-specific purification media to rapidly and efficiently separate mixtures of antibodies, antibody fragments and/or antibody components to isolate a desired antibody product from the mixture. The invention relates to the purification of bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, e.g., antibodies composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other a Lambda constant domain, including antibodies of different specificities that share a common heavy chain. The invention also provides the methods of efficiently purifying intact antibodies by separating the intact antibody from non-intact antibodies including free light chains.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: August 14, 2018
    Assignee: NovImmune SA
    Inventors: Greg Elson, Nicolas Fouque, Jean-Francois Depoisier, Nicolas Fischer, Giovanni Magistrelli
  • Patent number: 9974845
    Abstract: The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: May 22, 2018
    Assignee: CureVac AG
    Inventors: Mariola Fotin-Mleczek, Karl-Josef Kallen, Jochen Probst
  • Patent number: 9969813
    Abstract: The present invention is relevant to the generation of multi-specific antibodies, antibodies that are distinguished by their ability to bind to multiple antigens with specificity and with affinity. In particular, the present invention is related to bi-specific antibodies.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: May 15, 2018
    Assignee: BIOATLA, LLC
    Inventors: Gerhard Frey, Hwai Wen Chang, Jay M. Short
  • Patent number: 9891222
    Abstract: The present invention includes a semi-quantitative method for the detection of ENOX2 transcript variants from one or more anti-ENOX2 antibody-binding spots on a blot comprising the steps of: electrophoretically separating proteins from a concentrated blood, serum, or plasma sample from the subject; transferring the electrophoretically separated proteins to a substrate; separating the one or more ENOX2 transcript variants from the one or more anti-ENOX2 antibody-binding spots; and measuring an ENOX2-catalyzed conversion of an ionic silver or gold to a colloidal silver or gold detected by light scattering from the one or more anti-ENOX2 antibody binding spots on the substrate, wherein each of the one or more spots is indicative of the ENOX2 transcript variant. Also provided is the basis for a point of care test to detect ENOX2 transcript variants based on use of colloidal gold or silver complexes with ENOX2 as a rapid simple test for cancer presence.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: February 13, 2018
    Assignee: Mor-Nuco Enterprises, Inc.
    Inventors: D. James Morre, John Orczyk
  • Patent number: 9809799
    Abstract: The present application relates to novel and improved methods of achieving virus inactivation during a protein purification process.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: November 7, 2017
    Assignee: EMD Millipore Corporation
    Inventor: Alex Xenopoulos
  • Patent number: 9782500
    Abstract: The present invention relates to a novel anti-CD146 antibody and derivatives thereof. The antibody and/or derivatives can be used for therapy and/or imaging, diagnosis and/or immunostaining.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: October 10, 2017
    Assignee: Oncoinvent AS
    Inventors: Tina Bjørnlund Bønsdorff, Roy Hartvig Larsen
  • Patent number: 9732150
    Abstract: The present invention is directed to antibodies and fragments thereof (especially chimeric and humanized) having binding specificity for HGF and their use in therapy and diagnosis. These antibodies inhibit or block HGF-associated activities including HGF's effects on cell proliferation, invasion, angiogenesis, metastasis and fibrosis. Particularly the antibodies may be used as a monotherapy or in combination therapies in treating cancer, other proliferative disorders and other conditions wherein inhibition of HGF and/or the HGF/HGF-R (c-met) interaction is desired.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 15, 2017
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Leon F. Garcia-Martinez, Andrew L. Feldhaus, Katie Anderson, Benjamin H. Dutzar, John A. Latham
  • Patent number: 9580491
    Abstract: The invention provides non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing transgenic cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits. Certain aspects of the invention also relate to diagnostic and treatment methods using the antibodies of the invention.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: February 28, 2017
    Assignee: Ablexis, LLC
    Inventors: Larry Green, Hiroaki Shizuya
  • Patent number: 9523697
    Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: December 20, 2016
    Assignee: PROMIS NEUROSCIENCES Inc.
    Inventors: Neil Cashman, Marty Lehto
  • Patent number: 9485972
    Abstract: Described are novel N- and C-terminally double truncated tau molecules, (“type IA, IB, IIA and IIB tau molecules”) as well as methods for providing these molecules, both from recombinant and biological sources. Moreover, screening methods using these molecules in connection with Alzheimer's diagnosis and therapy are provided.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: November 8, 2016
    Assignee: Axon Neuroscience SE
    Inventor: Eva Kontsekovà
  • Patent number: 9481725
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for HGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-HGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-HGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-HGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with HGF.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 1, 2016
    Assignee: ALDERBIO HOLDINGS, LLC
    Inventors: Benjamin H. Dutzar, Katie Anderson, Brian R. Kovacevich, Andrew L. Feldhaus, John A. Latham, Leon F. Garcia-Martinez
  • Patent number: 9458239
    Abstract: The present invention relates to monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II) and their use for treating and diagnosing cancer diseases, such as ovarian cancers.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: October 4, 2016
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Isabelle Teulon, André Pelegrin
  • Patent number: 9453069
    Abstract: A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A?40, A?42, their ratio, or their rate of entry following administration of antibodies that sequester A?. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: September 27, 2016
    Assignees: ELI LILLY AND COMPANY, WASHINGTON UNIVERSITY
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, David J. Cummins, Steven M. Paul
  • Patent number: 9371375
    Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: June 21, 2016
    Assignee: Precision Biologics, Inc.
    Inventors: J. Andrew Bristol, Judith A. Kantor
  • Patent number: 9321992
    Abstract: In certain aspects, the invention relates to cell delivery compositions comprising a chondrogenic cell and a targeting moiety. Such compositions may be used, for example, in administering a targeted cell therapy to a subject.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: April 26, 2016
    Assignee: Case Western Reserve University
    Inventors: James E. Dennis, Arnold I. Caplan, Nir Cohen
  • Patent number: 9272031
    Abstract: The present invention relates to a purified antibody molecule preparation being characterized in that at least one antigen binding site comprises a glycosylated asparagine (Asn) in the variable region of the heavy chain (VH). More specifically, a pharmaceutical and a diagnostic composition comprising said antibody molecule and antibody mixtures are provided which is/are capable of specifically recognizing the ?-A4 peptide/A?4. The present invention relates in particular to a mixture of antibodies comprising one or two glycosylated antigen binding sites with a glycosylated asparagine (Asn) in the variable region of the heavy chain, i.e. mixtures of isoforms of antibodies which comprise a glycosylated Asn in the variable region of the heavy chain (VH). Also disclosed are compositions or antibody preparations comprising the specifically glycosylated antibody isoforms. Furthermore, the pharmaceutical and diagnostic uses for these antibodies are provided.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: March 1, 2016
    Assignee: F. Hoffmann-La Roche Inc.
    Inventors: Hansruedi Loetscher, Walter Huber, Diana Schuhbauer, Karl Weyer, Manfred Brockhaus, Bernd Bohrmann, Hans Koll, Andreas Schaubmar, Kurt Lang
  • Patent number: 9260532
    Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: February 16, 2016
    Assignee: Gilead Biologics, Inc.
    Inventors: Scott McCauley, Maria Vaysberg
  • Patent number: 9212225
    Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: December 15, 2015
    Assignee: AMPHIVENA THERAPEUTICS, INC.
    Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
  • Patent number: 9192663
    Abstract: This invention relates to antibodies or fragments thereof which interact with HER family of receptors, e.g., HER3 receptor. In particular, it relates to antibodies or fragments thereof that recognize a conformational epitope of HER3 receptor comprising residues from both domains 2 and 4 resulting in inhibition of both ligand-dependent and ligand-independent signal transduction; and allow ligand binding (e.g., neuregulin), while preventing ligand-induced activation of signal transduction. These antibodies or fragments can be used to treat a number of diseases or disorders characterized by increased levels of HER3 expression (e.g., esophageal cancer). These antibodies or fragments can be used to treat a number of diseases or disorders characterized by the antibodys or fragments ability to decrease tissue weight (e.g., prostate or uterine weights) or to induce atrophy of tissue (e.g., atrophy of male breast).
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: November 24, 2015
    Assignee: NOVARTIS AG
    Inventors: Winfried Elis, Seth Ettenberg, Andrew Paul Garner, Nicole Haubst, Xizhong Huang, Christian Carsten Silvester Kunz, Elizabeth Anne Reisinger Sprague, Qing Sheng
  • Patent number: 9187558
    Abstract: An isolated monoclonal antibody or an antigen-binding fragment thereof is disclosed. The antibody or the antigen-binding fragment is characterized by: (a) having a specific binding affinity to epithelial cell adhesion molecule (EpCAM) comprising the amino acid sequence of SEQ ID NO: 1; (b) having a specific binding affinity to cancer cells expressing EpCAM said cancer cells being selected from the group consisting of oral cancer cells, nasopharyngeal cancer cells (NPC), colorectal cancer cells, and ovarian cancer cells; and (c) having no binding affinity to human umbilical vein endothelial cell (HUVEC) and normal nasal mucosal epithelia (NNM). Also disclosed is an isolated monoclonal antibody or an antigen-binding fragment thereof that has a specific binding affinity to an epitope within the sequence of KPEGALQNNDGLYDPDCDE (SEQ ID NO: 63) located within the EGF-like domain II of epithelial cell adhesion molecule (EpCAM). Methods of using the same are also disclosed.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: November 17, 2015
    Assignee: Academia Sinica
    Inventors: Han-Chung Wu, Mei-Ying Liao, Cheng-Wei Lin
  • Patent number: 9181332
    Abstract: An anti-A? oligomer humanized antibody which does not bind to A? monomers and specifically binds only to A? oligomers; an anti-cognitive dysfunction agent, an agent for treating Alzheimer's disease, an agent for suppressing formation of neuritic plaque and an inhibitor of formation of A? amyloid fiber comprising the antibody as an active ingredient; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the antibody.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: November 10, 2015
    Assignee: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Tsuguo Kubota, Nobuyuki Suzuki
  • Patent number: 9164108
    Abstract: This invention provides novel liposome-based articles of manufacture and microarrays and methods of making and using them (1) to detect the presence of one or more agents in a sample, (2) to determine the amount of one or more agents in a sample, and (3) to determine whether a subject is afflicted with a disorder. This invention also provides kits which comprise the instant microarrays.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: October 20, 2015
    Assignee: SRI INTERNATIONAL
    Inventors: Denong Wang, Leonore A. Herzenberg, Lawrenes Steinman
  • Patent number: 9103832
    Abstract: Disclosed is a therapeutic method including administering a TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(?)CD34(+)CD38(?) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody or its TIM-3 binding fragment to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)).
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: August 11, 2015
    Assignees: KYOWA HAKKO KIRIN CO., LTD., Kyushu University, National University Corporation
    Inventors: Shinichiro Takayanagi, Yoshimasa Inagaki, Koichi Akashi, Yoshikane Kikushige
  • Patent number: 9062104
    Abstract: The present invention is directed to antibodies and fragments thereof (especially chimeric and humanized) having binding specificity for HGF and their use in therapy and diagnosis. These antibodies inhibit or block HGF-associated activities including HGF's effects on cell proliferation, invasion, angiogenesis, metastasis and fibrosis. Particularly the antibodies may be used as a monotherapy or in combination therapies in treating cancer, other proliferative disorders and other conditions wherein inhibition of HGF and/or the HGF/HGF-R (c-met) interaction is desired.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 23, 2015
    Assignee: ALDERBIO HOLDINGS LLC
    Inventors: Leon F. Garcia-Martinez, Andrew Lawrence Feldhaus, Katie Anderson, Benjamin H. Dutzar, John A. Latham
  • Patent number: 9045725
    Abstract: The present invention relates to a process and apparatus for purifying a molecule of interest from a heterogeneous clarified fluid mixture. The apparatus of the invention generally comprises a continuous perfusion fermentation system, a continuous particle removal system integrated with the perfusion fermentation system; and a continuous purification system integrated with the particle removal system, which is maintained under sterile conditions. The process comprises filtering a heterogeneous clarified fluid mixture by continuous ultrafiltration at a specific flow rate below the transition point of the molecule of interest in the pressure-dependent region of the flux versus TMP curve, wherein the specific flow rate is maintained substantially constant throughout the continuous ultrafiltration.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: June 2, 2015
    Assignee: Bayer Healthcare LLC
    Inventors: Jens Holger Vogel, Roberto Giovannini, Konstantin B. Konstantinov, Huong My Nguyen, Paul Wu
  • Publication number: 20150147274
    Abstract: Antibodies which are antagonists of the human HGF receptor (MET), wherein the antibodies specifically bind to amino acid residues 568-741 of human MET (SEQ ID No: 1) with high affinity.
    Type: Application
    Filed: November 30, 2012
    Publication date: May 28, 2015
    Inventors: Danielle Marie Di Cara, John McCafferty, Ermanno Gherardi, Anthony Richard Pope
  • Publication number: 20150139983
    Abstract: The invention provides pharmaceutical compositions for the treatment of neuroinflammatory or neurodegenerative diseases comprising a single or a combination of several blocking agent(s) of Bone Morphogenic Protein (BMP) signaling. The invention further provides methods of treatment of neuroinflammatory or neurodegenerative diseases comprising administering to a patient in need thereof the pharmaceutical compositions of the invention.
    Type: Application
    Filed: June 12, 2013
    Publication date: May 21, 2015
    Inventors: Arnon Karni, Yifat Amir Levi, Nataly Urshanski, Karin Bernadet Fainberg
  • Patent number: 9035026
    Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: May 19, 2015
    Assignee: Affimed GMBH
    Inventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
  • Publication number: 20150133643
    Abstract: Provided is a primary clarification depth filtration process of cell-culture feeds, including chemically treated flocculated feeds, containing target biomolecules of interest such as mAbs, mammalian cell cultures, or bacterial cell cultures, utilizing a primary clarification depth filtration device containing a media with significantly lower flushing requirements, resulting in lower levels of organic extractables released after media flushing, and increased throughput for the pre-treated feed streams, without the use of a primary clarification centrifugation step or primary clarification tangential flow microfiltration step. The primary clarification depth filtration device used in the primary clarification of fluid cell culture feeds, including chemically treated flocculated feeds containing flocculated cellular debris and/or colloidal particulates having a particle size distribution of about 0.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 14, 2015
    Inventors: Kwok-Shun Cheng, Nripen Singh
  • Publication number: 20150133642
    Abstract: This application teaches methods for crystallizing antibodies from cell-free culture supernatants. They produce high purity, stable, crystallized monoclonal antibodies suitable for formulation in pharmaceutical products in high yield from cell-free culture supernatant without the use of costly steps or equipment.
    Type: Application
    Filed: May 10, 2013
    Publication date: May 14, 2015
    Inventors: Dariusch Hekmat, Bernhard Helk, Henk Konrad Schulz, Benjamin Smejkal
  • Patent number: 9028826
    Abstract: Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: May 12, 2015
    Assignee: The Trustees of Dartmouth College
    Inventor: Randolph J. Noelle
  • Patent number: 9029515
    Abstract: The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH (i.e., pH 6.0 or 5.5). In other words, the KD or koff ratio at pH 5.5/pH 7.4 or at pH 6.0/pH 7.4 is more than, or ranges between, 2, 3, 4, 8, 10, 16, 20, 30, 40, or 100 or more. Such pH dependent antibodies preferentially dissociate from the antigen in the endosome. This can increase antibody half life, as compared to antibodies with equivalent KDs at pH 7.4 but with no pH dependent binding, when the antigen is one that undergoes antigen-mediated clearance (e.g., PCSK9). Antibodies with pH dependent binding can decrease total antigen half life when the antigen undergoes reduced clearance when bound to antibody (e.g., IL6). Antibodies with pH dependent binding can also prolong the decrease in antigen which is not antibody-bound.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: May 12, 2015
    Assignees: Rinat Neuroscience Corp., Pfizer Inc.
    Inventors: Jaume Pons, Jeffrey Raymond Chabot, Javier Fernando Chaparro Riggers, Bruce Charles Gomes, Hong Liang, Kapil Mayawala, Jerome Thomas Mettetal, II, Arvind Rajpal, David Louis Shelton
  • Patent number: 9029508
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: May 12, 2015
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
  • Patent number: 9028816
    Abstract: The present invention relates to polypeptides and polypeptide constructs comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, homologues of said polypeptides, and/or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation.
    Type: Grant
    Filed: January 9, 2004
    Date of Patent: May 12, 2015
    Assignee: Ablynx N.V.
    Inventor: Karen Silence
  • Patent number: 9029512
    Abstract: The present invention relates to antibodies that immunospecifically bind to phospho-Akt and certain p-Akt substrates. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to p-Akt-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: May 12, 2015
    Assignee: Nuclea Biotechnologies, Inc.
    Inventor: Patrick J. Muraca
  • Patent number: 9028833
    Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: May 12, 2015
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, David M. Goldenberg
  • Publication number: 20150125929
    Abstract: The present invention relates to novel and improved methods for the purification of biomolecules. In particular, the present invention relates to methods of protein purification which employ a porous solid support modified with a charged fluorocarbon composition.
    Type: Application
    Filed: March 18, 2013
    Publication date: May 7, 2015
    Inventors: Mikhail Kozlov, Wilson Moya, Jad Jaber, William Cataldo, Ajish Potty, Christopher Gillespie
  • Patent number: 9023999
    Abstract: The present invention provides a monoclonal antibody which specifically recognizes CD27 containing an O-linked sugar chain to which galactose is not bound and binds to its extracellular region, or a method for using the same. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which specifically recognizes a polypeptide encoded by CD27 gene containing an O-linked sugar chain to which galactose is not bound, and binds to its extracellular region; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent comprising the antibody or the antibody fragment thereof as an active ingredient.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: May 5, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Katsuhiro Mori, Naoko Hiura, Tsuguo Kubota, Akiko Furuya, Yutaka Kanda, Mitsuo Satoh
  • Patent number: 9023358
    Abstract: The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: May 5, 2015
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Daniel Scott Girard, Kristine Kay Kikly
  • Patent number: 9023353
    Abstract: The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of methamphetamine use, or for slowing the rate of (+) methamphetamine entry into the brain of a subject. The method comprises administering an effective amount of an anti-(+) methamphetamine antibody to a subject.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: May 5, 2015
    Assignee: The Board of Trustees of the University of Arkansas
    Inventors: Samuel Michael Owens, Ralph Henry, Alicia Brown
  • Publication number: 20150118230
    Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
    Type: Application
    Filed: February 15, 2013
    Publication date: April 30, 2015
    Inventors: Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
  • Publication number: 20150118235
    Abstract: An antibody that binds a MeCP2E1 isoform of MeCP2 protein, wherein the antibody comprises a region comprising the amino acid sequence of SEQ ID NO:4. A method for detecting and/or monitoring a disease or a disorder caused by an over-expression or an under-expression of a MeCP2E1 isoform of MeCP2 protein, comprising the steps of: (i) obtaining a first sample from a mammalian subject; (ii) contacting the first sample with the anti-MeCP2E1antibody; (iii) removing unbound antibody from the sample; (iv) conducting an immunoassay on the first sample to determine a first value for expression of the MeCP2E1 isoform; (v) comparing the first value to a reference value for expression of the MeCP2E1 isoform in healthy mammalian subjects; wherein a deviation of the first value from the reference value indicates the presence of a disease or a disorder caused by an over-expression or an under-expression of the MeCP2E1 isoform.
    Type: Application
    Filed: October 24, 2013
    Publication date: April 30, 2015
    Applicant: University of Manitoba
    Inventor: Mojgan Rastegar
  • Patent number: 9018357
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: April 28, 2015
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic Fellouse, Sachdev S. Sidhu, Christian Wiesmann